Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470686 | 0.73 | MEN1 (0.63) | KMT2AMEN1RAB9APOLBALDH1A1 | |
| SCHEMBL21020549 | 0.71 | TDP1 (0.44) | KMT2AMEN1RAB9AMAPTPOLB | |
| SCHEMBL20831063 | 0.70 | KMT2A (0.43) | KMT2AMEN1RAB9AMAPTPOLB | |
| SCHEMBL20076688 | 0.69 | GABRA1 (0.41) | KMT2AMEN1RAB9APOLBALDH1A1 | |
| SCHEMBL21022200 | 0.69 | KDM4E (0.54) | KMT2AL3MBTL1MEN1RAB9AMAPT | |
| SCHEMBL21021757 | 0.68 | MEN1 (0.54) | KMT2AL3MBTL1MEN1RAB9AMAPT | |
| SCHEMBL21019686 | 0.68 | RAB9A (0.42) | KMT2AL3MBTL1MEN1RAB9AMAPT | |
| SCHEMBL21021625 | 0.67 | RAB9A (0.41) | KMT2AL3MBTL1MEN1RAB9AMAPT | |
| SCHEMBL21022158 | 0.67 | RORC (0.47) | KMT2AMEN1RAB9AMAPTPOLB | |
| SCHEMBL21020666 | 0.67 | F10 (0.47) | KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011097600-A1 | SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY | THE WISTAR INSTITUTE (US) | 2011-08-11 | — | — | WO | disclosed |